Impact of endogenous insulin secretion on the improvement of glucose variability in Japanese patients with type 2 diabetes treated with canagliflozin plus teneligliptin.

Aika Miya Akinobu Nakamura Kyu Yong ChoShinichiro KawataHiroshi NomotoSo NagaiHajime SugawaraShinji TanedaKazuhisa TsuchidaKazuno OmoriHiroki YokoyamaJun TakeuchiShin AokiYoshio KuriharaTatsuya Atsumi Hideaki Miyoshi

Published in: Journal of diabetes investigation (2021)

COMB would be a better protocol rather than switching teneligliptin to canagliflozin to improve daily glucose variability in patients with impaired endogenous insulin secretion.

Keyphrases

blood glucose
randomized controlled trial
physical activity
type diabetes
blood pressure
metabolic syndrome
newly diagnosed
skeletal muscle
adipose tissue